本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 桂林莱茵生物科技股份有限公司（以下简称"公司"）正在筹划控制权变更、 发行股份及支付现金购买资产并募集配套资金事项（以下简称"本次交易"）。因 有关事项尚存在不确定性，为了维护投资者利益，避免对公司证券交易造成重大影 响，根据深圳证券交易所的相关规定，经公司向深圳证券交易所申请，公司股票（证 券简称：莱茵生物，证券代码：002166）自 2025 年 12 月 10 日（星期三）开市时起 开始停牌，预计连续停牌时间不超过 10 个交易日。具体内容详见公司在指定信息披 露媒体《中国证券报》《证券时报》《证券日报》《上海证券报》和巨潮资讯网 （www.cninfo.com.cn）刊登的《关于筹划控制权变更、发行股份及支付现金购买资 产并募集配套资金事项的停牌公告》（公告编号：2025-072）。 桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2025-073 桂林莱茵生物科技股份有限公司 关于筹划控制权变更、发行股份及支付现金购买资产 并募集配套资金事项停牌的进展公告 二〇二五年 ...

莱茵生物公告，公司正在筹划控制权变更、发行股份及支付现金购买资产并募集配套资金事项。因有关 事项尚存在不确定性，公司股票自2025年12月10日开市时起开始停牌，预计连续停牌时间不超过10个交 易日。截至本公告披露日，公司以及有关各方正在积极推进本次交易的各项工作，相关各方正在就交易 方案进行协商、论证和确认。为维护投资者利益，避免公司证券交易价格出现异常波动，根据深圳证券 交易所的相关规定，公司股票将继续停牌。 ...

证券日报网讯12月10日，莱茵生物（002166）在互动平台回答投资者提问时表示，公司植物提取产能充 足，目前备有一定的莽草酸存货，可随时响应市场需求。 ...

Core Viewpoint - Rhein Biotech, a leader in the plant extraction industry, is undergoing a significant change in control and asset acquisition, led by Defu Capital, which manages over $34 billion in funds, aiming to inject strong growth momentum into the company [1][2]. Group 1: Company Overview - Rhein Biotech has over 300 standardized plant extraction technologies and has established multiple national-level research platforms, including a "National Tropical Fruit Processing Technology R&D Center" and a "Postdoctoral Research Station" [1]. - The company holds a stable global market share of 20%-25% in monk fruit extract and ranks among the top three globally in stevia extract sales [1]. Group 2: Capital Cooperation - Defu Capital, a seasoned investment institution in the healthcare and consumer sectors, is acquiring control through its Guangzhou Defu Nutrition Investment platform, with 99.926% of the investment coming from its core operating entity, reflecting strong confidence in Rhein Biotech's future [2]. - The acquisition includes Beijing Jinkangpu Food Technology Co., a leading company in the food premix sector, which has three modern production bases and a capacity of over 10,000 tons [2]. Group 3: Strategic Synergy - The collaboration between Rhein Biotech and Jinkangpu is expected to create a robust industrial ecosystem, where Rhein's natural raw materials will supply Jinkangpu's production system, ensuring quality raw materials for end products [2]. - Jinkangpu's strong customer base and international channels will open new markets for Rhein's high-value products, enhancing product value significantly [2]. Group 4: Future Prospects - The partnership is anticipated to accelerate the transformation of technology for Rhein Biotech, integrating its R&D capabilities with Jinkangpu's application strengths in food and health products [3]. - As consumer demand for "natural health" continues to rise, this strategic alliance is expected to further solidify Rhein Biotech's leading position in the global natural health products market [3].

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：公司目前是满产吗？客户需要排队预约吗？ 莱茵生物（002166.SZ）12月10日在投资者互动平台表示，公司植物提取产能充足，目前备有一定的莽 草酸存货，可随时响应市场需求。 ...

Group 1 - Jinggong Technology signed a sales contract with Hubei Yuchuang worth 729 million yuan, accounting for 42.16% of the company's audited revenue for 2024 [1] - Heshun Electric is expected to win a bid for a State Grid procurement project worth 107 million yuan, representing 24.97% of the company's 2024 revenue [2] - Yongmaotai plans to invest approximately 400 million yuan in a new intelligent manufacturing project for magnesium-aluminum alloy materials [3] Group 2 - Longi Green Energy announced the termination of its plan to issue global depositary receipts abroad, stating it will not significantly impact its operations [4] - Bai Ao Intelligent is expected to win bids for projects totaling 27.5 million yuan [5] - Lian Biological is planning a change of control and asset purchase, leading to a temporary suspension of its stock [6] Group 3 - Bo Rui Communication intends to acquire 51% of Meijing Technology for 66.49 million yuan [7] - Huitai Medical plans to repurchase shares worth 200 to 250 million yuan for employee stock ownership plans [8] - Yifang Biological is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange [9] Group 4 - Jiuqiang Biological's shareholders signed an agreement for the transfer of 5% of the company's shares to China National Pharmaceutical Investment [11] - Songcheng Performing Arts plans to repurchase shares worth 100 to 200 million yuan for capital reduction [12] - Zhonghong Medical's subsidiary is expected to be selected for a centralized procurement project in Jiangxi Province [13] Group 5 - Xingfu Electronics plans to invest 480 million yuan in a new electronic-grade phosphoric acid project [14] - Jiaao Environmental Protection's stock will be subject to risk warnings due to an administrative penalty [15] - ST Nuotai received a drug registration certificate for a new injection [16] Group 6 - Haimo Technology plans to sell its controlling subsidiary, Xian Sitian Instrument, for 370 million yuan [17] - Jingce Electronics signed multiple sales contracts with a single customer totaling 433 million yuan [18] - Donghua Testing's controlling shareholder plans to reduce its stake by up to 1.99% [19][20] Group 7 - Xingqi Eye Medicine completed the first subject enrollment for a Phase II clinical trial of its eye drop product [21] - Kute Intelligent's controlling shareholder plans to reduce its stake by up to 2% [22] - Dongcheng Pharmaceutical's subsidiary received approval for a new specification of a heparin sodium injection [23] Group 8 - Zhaoyi Innovation is in the process of issuing H-shares and has received regulatory approval [24] - Aokang International's shareholder plans to reduce its stake by up to 3% [25] - Jiamei Packaging's controlling shareholder is planning a change of control, leading to a temporary stock suspension [26] Group 9 - ST Kevin's stock will have its risk warning lifted and will resume trading [27] - Zaiseng Technology's controlling shareholder plans to transfer 6.04% of the company's shares [28] - Lide New Energy's shareholder plans to reduce its stake by up to 1% [29] Group 10 - Srypu terminated its plan to acquire shares and will resume trading [30] - Longjiang Transportation's subsidiary plans to invest 2.679 billion yuan in a graphite mining project [31] - Haowei Group's controlling shareholder has not reduced its stake and has terminated the reduction plan [32] Group 11 - Huilun Crystal received an administrative penalty notice for information disclosure violations [33] - Haiguang Information terminated a major asset restructuring plan [34] - Zhongke Shuguang announced a cash dividend plan [35] Group 12 - Fushuo Technology's share purchase plan was approved by the Shenzhen Stock Exchange [36] - Dongbai Group's shareholder reduced its stake by 25.95 million shares [38]

Core Viewpoint - In December, 49 institutions conducted a total of 222 "buy" ratings covering 185 stocks, indicating a strong interest in certain companies despite a general decline in the food and beverage sector [2][5]. Group 1: Institutional Ratings - Eight stocks received ratings from three or more institutions, with BYD and Shanxi Fenjiu leading with five ratings each [2][3]. - Other notable stocks with three ratings include Kweichow Moutai, Anjuke Food, Hangyang Co., and Yutong Bus [3]. Group 2: Company Performance - BYD reported a year-on-year production increase of 7.29% and sales growth of 11.3% for the first eleven months of the year, highlighting strong performance in the electric vehicle sector [3]. - Shanxi Fenjiu achieved a revenue of 32.92 billion yuan in the first three quarters, a 5% increase year-on-year, with a net profit of 11.41 billion yuan, reflecting a 0.48% growth [4]. Group 3: Market Trends - The food and beverage industry index has declined by 3.6% in December, underperforming the CSI 300 index by approximately 5 percentage points, yet it still attracted a net inflow of 1.209 billion yuan [5]. - The white liquor industry is expected to benefit from favorable policies, including measures to support sales and exports [5]. Group 4: Company Developments - Rhein Biotech announced plans to acquire at least 80% of Beijing Jinkangpu Food Technology Co., enhancing its capabilities in the food and beverage sector [8]. - The company is also undergoing a potential change in control, with its major shareholder planning to transfer some shares, which may lead to a change in the controlling entity [9].

Core Viewpoint - The actual controller of Rhein Biotech, Qin Benjun, is planning a change in the company's control, leading to a stock suspension and a potential acquisition of at least 80% of Beijing Jinkangpu Food Technology Co., Ltd. [1][2][5] Group 1: Control Change - Qin Benjun is preparing to transfer part of his shares and relinquish voting rights, indicating a potential change in control of Rhein Biotech [2][5] - A "Control Change Intent Agreement" has been signed by relevant parties, but specific transaction details are still under negotiation [5] - The transaction may result in a change of the controlling shareholder and actual controller of the company [5] Group 2: Acquisition Details - Rhein Biotech plans to acquire at least 80% of Beijing Jinkangpu, which will become a subsidiary and included in the consolidated financial statements [5][9] - The acquisition aims to enhance Rhein Biotech's capabilities in food and health product development, leveraging synergies between the two companies [9] Group 3: Company Background - Rhein Biotech specializes in the research, production, and sales of natural health products and is a leading player in the global plant extraction industry [12] - As of the end of the third quarter, Qin Benjun holds 271.39 million shares, representing 36.59% of the company [10][11] - The company's stock price was reported at 8.7 yuan per share, with a total market value of 64.52 billion yuan as of December 9 [13]

Core Viewpoint - The actual controller of Rhein Biotech, Qin Benjun, is planning a change in the company's control, leading to a stock suspension and a proposed acquisition of at least 80% of Beijing Jinkangpu Food Technology Co., Ltd. [2][4][9] Group 1: Control Change - Rhein Biotech announced that Qin Benjun is preparing to transfer part of his shares and relinquish some voting rights [4][7] - A "Control Change Intent Agreement" has been signed, but specific transaction details are still under negotiation [7][8] - The change may result in a new controlling shareholder and actual controller for the company [7] Group 2: Acquisition Details - The company plans to acquire at least 80% of Beijing Jinkangpu, which will become a subsidiary and included in the consolidated financial statements [7][14] - The acquisition aims to leverage synergies between Rhein Biotech and Beijing Jinkangpu, enhancing R&D capabilities and market coverage [14] - Beijing Jinkangpu's parent company has extensive experience in the infant food and health supplement sectors, collaborating with well-known dairy companies [11][14] Group 3: Shareholding Structure - As of the end of Q3, Qin Benjun holds 271.39 million shares, representing 36.59% of Rhein Biotech [15][16] - The total market value of Qin's shares is approximately 2.15 billion [16] - The company’s stock price was reported at 8.7 yuan per share, with a total market capitalization of 6.45 billion as of December 9 [18]

Industry News - A new polysilicon platform company named Beijing Guanghe Qiancheng Technology Co., Ltd. has been registered with a capital of 3 billion, established on December 9, 2025, in Beijing. The company aims to explore potential strategic cooperation opportunities within the industry, such as technology upgrades and market expansion [25][25]. - The National Retail Innovation Development Conference is being held in Beijing from December 9 to 10. The Deputy Minister of Commerce, Sheng Qiuping, emphasized the need for further improvement in retail layout, supply-demand matching, and online-offline balance, while also encouraging the development of new business models and scenarios to stimulate consumer potential [25][25]. - The State Administration for Market Regulation has approved the release of two mandatory national standards for civil unmanned aerial vehicles, which will take effect on May 1, 2026 [25][25]. - Alibaba has established the Qianwen C-end Business Group, aiming to develop Qianwen into a super app and the primary entry point for users in the AI era [26][26]. - Huawei's 2012 Lab has established a foundational model department focused on advancing base model development and is actively recruiting young research talents with outstanding academic backgrounds [26][26]. - The Ministry of Agriculture and Rural Affairs reported that pork supply in November was sufficient, with prices slightly decreasing. The average daily market volume of pork in Beijing's Xinfadi market was 2,128.8 heads, a 10.57% increase from October and a 7.54% increase year-on-year [26][26]. - The National Development and Reform Commission indicated that the coking coal market shifted from tight to loose in November, with price expectations declining. The coking coal price expectation index fell to below the 50% threshold, indicating weak support for the market [26][26]. Company News - Jiaao Environmental Protection announced that due to false records in the 2022 and 2023 annual reports, the company's stock will be subject to other risk warnings [27][27]. - Huilun Crystal also announced that its 2021 and 2022 annual reports contained false records, leading to similar risk warnings for its stock [27][27]. - Haiguang Information announced the termination of its major asset restructuring with Zhongke Shuguang [28][28]. - Zhongke Shuguang announced the termination of its share swap absorption merger with Haiguang Information and the associated fundraising [29][29]. - Tianyuan Dike announced that its chairman, Chen You, has been placed under detention [30][30]. - Lain Biological announced that its controlling shareholder is planning a change of control and intends to acquire at least 80% of Beijing Jinkangpu's shares, leading to a stock suspension [30][30]. - Shengyi Technology announced an investment of approximately 198 million yuan to build an annual production project of 2,400 tons of ultra-high molecular weight polyethylene fiber, expanding its application value in humanoid robots [30][30]. - HoloWave announced a significant increase in orders for satellite testing systems, primarily from commercial aerospace satellite manufacturers and testing service providers [30][30]. - Longi Green Energy announced the termination of its overseas issuance of global depositary receipts [31][31]. - Zaiseng Technology announced that its controlling shareholder, Guo Mao, plans to transfer 6.04% of the company's shares to Zhongrong Huaxin [31][31]. - Si Rui Pu announced the termination of its plan to acquire shares of Aola, and its stock will resume trading [32][32]. - Fosun Pharma announced that its subsidiary, Yaoyou Pharmaceutical, has signed a licensing agreement with Pfizer [33][33].